The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
PPARs and nonalcoholic fatty liver disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis. Without intervention it can progress to end-stage liver disease and hepatocellular carcinoma. Given its close association with obesity, the prevalence of NAFLD has increased dramatically worldwide. Currently, there are no FDA-approved medications for the treatment of NAFLD and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients. As such, the search for effective therapeutic agents is an active area of research. Peroxisome proliferator-activated receptors (PPARs) belong to a class of nuclear receptors. Because of their key role in the transcriptional regulation of glucose and lipid metabolism, PPAR ligands have been investigated as possible therapeutic agents for NAFLD. Here we review the current evidence from preclinical and clinical studies investigating the therapeutic potential of PPAR ligands for the treatment of this spectrum of liver disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176 · cited 1×
“PPARγ activation by TZDs results in increased production of various adipokines, including adiponectin, which enhances hepatic fatty acid oxidation [1,76,77].”
BackgroundPeroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 4×
“Studies estimate that 37–41% of NAFLD patients show fibrosis progression in follow up biopsies [6,8].”
BackgroundInfluentialEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
PPARs and the complex journey to obesity
Evans, R. M., Barish, G. D., & Wang, Y.-X. (2004) · Nature Medicine · doi:10.1038/nm1025 · Cited by 1,602
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Prevalence of Fatty Liver in Children and Adolescents
Schwimmer, J. B., Deutsch, R., Kahen, T., Lavine, J. E., Stanley, C., & Behling, C. (2006) · Pediatrics · doi:10.1542/peds.2006-1212 · Cited by 1,481
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 3×
“polymorphisms in PNPLA3 [12] and TM6SF2 [13] genes are associated with increased susceptibility to NAFLD and certain variants may be associated with more rapid progression to NASH [1,14] by mechanisms that are poorly understood.”
BackgroundPeroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3216-3 · Cited by 1,218
Charlton, M. R., Burns, J. M., Pedersen, R. A., Watt, K. D., Heimbach, J. K., & Dierkhising, R. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.061 · Cited by 1,106
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y.-X., & Diehl, A. M. (2007) · Hepatology · doi:10.1002/hep.21655 · Cited by 1,015
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids
Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M., & Lazar, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23975 · Cited by 711
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“However, there was no significant improvement in other histological features such as fibrosis, hepatocyte ballooning and inflammation [89].”
BackgroundYu, S., Matsusue, K., Kashireddy, P., Cao, W.-Q., Yeldandi, V., Yeldandi, A. V., Rao, M. S., Gonzalez, F. J., & Reddy, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210062200 · Cited by 619
Matsusue, K., Haluzik, M., Lambert, G., Yim, S.-H., Gavrilova, O., Ward, J. M., Brewer, B., Reitman, M. L., & Gonzalez, F. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317223 · Cited by 585
Laurin, J., Lindor, K. D., Crippin, J. S., Gossard, A., Gores, G. J., Ludwig, J., Rakela, J., & McGill, D. B. (1996) · Hepatology · doi:10.1002/hep.510230624 · Cited by 566
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 556
Pathogenesis of Nonalcoholic Steatohepatitis
Machado, M. V., & Diehl, A. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.066 · Cited by 539
Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease
Kohjima, M., Enjoji, M., Higuchi, N., Kato, M., Kotoh, K., Yoshimoto, T., Fujino, T., Yada, M., Yada, R., Harada, N., et al. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.20.3.351 · Cited by 529
Motojima, K., Passilly, P., Peters, J. M., Gonzalez, F. J., & Latruffe, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16710 · Cited by 524
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Animal models of nonalcoholic fatty liver disease
Hebbard, L., & George, J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.191 · Cited by 499
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476
Peroxisome proliferator activated receptor-alpha expression in human liver.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · PubMed · Cited by 448
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Peroxisome Proliferator Activated Receptor-α Expression in Human Liver
Palmer, C. N. A., Hsu, M.-H., Griffin, K. J., Raucy, J. L., & Johnson, E. F. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.1.14 · Cited by 416
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
Morán‐Salvador, E., López‐Parra, M., García‐Alonso, V., Titos, E., Martínez‐Clemente, M., González‐Périz, A., López‐Vicario, C., Barak, Y., Arroyo, V., & Clària, J. (2011) · The FASEB Journal · doi:10.1096/fj.10-173716 · Cited by 389
Ip, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
Zhu, Y., Alvares, K., Huang, Q., Rao, M. S., & Reddy, J. K. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74184-2 · Cited by 374
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Pettinelli, P., & Videla, L. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2129 · Cited by 351
Patsouris, D., Reddy, J. K., Müller, M., & Kersten, S. (2006) · Endocrinology · doi:10.1210/en.2005-1132 · Cited by 340
Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., et al. (2008) · Diabetes · doi:10.2337/db07-1318 · Cited by 325
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Chalasani, N., Guo, X., Loomba, R., Goodarzi, M. O., Haritunians, T., Kwon, S., Cui, J., Taylor, K. D., Wilson, L., Cummings, O. W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.057 · Cited by 315
Sznaidman, M. L., Haffner, C. D., Maloney, P. R., Fivush, A., Chao, E., Goreham, D., Sierra, M. L., LeGrumelec, C., Xu, H. E., Montana, V. G., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00207-5 · Cited by 312
A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
Basaranoglu, M., Acbay, O., & Sonsuz, A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80243-8 · Cited by 305
Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
Rakhshandehroo, M., Hooiveld, G., Müller, M., & Kersten, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006796 · Cited by 305
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
Roles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
Gonzalez, F. J., & Shah, Y. M. (2008) · Toxicology · doi:10.1016/j.tox.2007.09.030 · Cited by 262
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 256
PPARα Expression Protects Male Mice from High Fat–Induced Nonalcoholic Fatty Liver1–3
Abdelmegeed, M. A., Yoo, S.-H., Henderson, L. E., Gonzalez, F. J., Woodcroft, K. J., & Song, B.-J. (2011) · The Journal of Nutrition · doi:10.3945/jn.110.135210 · Cited by 251
Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model
Kim, S., Sohn, I., Ahn, J.-I., Lee, K.-H., Lee, Y. S., & Lee, Y. S. (2004) · Gene · doi:10.1016/j.gene.2004.06.015 · Cited by 248
Shiri-Sverdlov, R., Wouters, K., Gorp, P. J. V., Gijbels, M. J., Noel, B., Buffat, L., Staels, B., Maeda, N., Bilsen, M. V., & Hofker, M. H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.033 · Cited by 241
Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233
A Paradigm for Gene Regulation: Inflammation, NF-κB and PPAR
Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., & Haegeman, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9072-3_22 · Cited by 222
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
McCommis, K. S., Chen, Z., Fu, X., McDonald, W. G., Colca, J. R., Kletzien, R. F., Burgess, S. C., & Finck, B. N. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.028 · Cited by 213
Self-citationHenry, R. R., Lincoff, A. M., Mudaliar, S., Rabbia, M., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 205
Holden, P., & Tugwood, J. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0220001 · Cited by 201
Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation
Stienstra, R., Mandard, S., Patsouris, D., Maass, C., Kersten, S., & Müller, M. (2007) · Endocrinology · doi:10.1210/en.2007-0014 · Cited by 191
Patton, H. M., Yates, K., Unalp-Arida, A., Behling, C. A., Huang, T. T.-K., Rosenthal, P., Sanyal, A. J., Schwimmer, J. B., & Lavine, J. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.152 · Cited by 185
Torres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876992 · Cited by 180
Cariou, B., Zaïr, Y., Staels, B., & Bruckert, E. (2011) · Diabetes Care · doi:10.2337/dc11-0093 · Cited by 172
Juurlink, D. N., Gomes, T., Lipscombe, L. L., Austin, P. C., Hux, J. E., & Mamdani, M. M. (2009) · BMJ · doi:10.1136/bmj.b2942 · Cited by 170
Kawaguchi, K., Sakaida, I., Tsuchiya, M., Omori, K., Takami, T., & Okita, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.038 · Cited by 160 · cited 4×
“Concomitant in vitro studies illustrated decreased activation of hepatic stellate cells treated with pioglitazone [80].”
BackgroundInfluentialBays, H. E., Schwartz, S. L., Littlejohn, T. W., Kerzner, B., Krauss, R. M., Karpf, D. B., Choi, Y., Wang, X., Naim, S., & Roberts, B. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1061 · Cited by 157
Ye, J., Iglesias, M. A., Watson, D. G., Ellis, B. A., Wood, L., Jensen, P. B., Sørensen, R. V., Larsen, P. J., Cooney, G. J., Wassermann, K., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00299.2002 · Cited by 146
Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice†
García‐Ruíz, I., Rodríguez‐Juan, C., Díaz-Sanjuán, T., Martínez, M. Á., Muñoz‐Yagüe, T., & Solis-Herruzo, J. A. (2007) · Hepatology · doi:10.1002/hep.21687 · Cited by 127
Esposito, K., Ciotola, M., Carleo, D., Schisano, B., Saccomanno, F., Sasso, F. C., Cozzolino, D., Assaloni, R., Merante, D., Ceriello, A., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2174 · Cited by 123
Chen, Z., Vigueira, P. A., Chambers, K. T., Hall, A. M., Mitra, M. S., Qi, N., McDonald, W. G., Colca, J. R., Kletzien, R. F., & Finck, B. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.363960 · Cited by 122
Self-citationPathogenesis of NASH: Animal Models
London, R. M., & George, J. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.010 · Cited by 117
Diet-induced obesity and hepatic gene expression alterations in C57BL/6J and ICAM-1-deficient mice
Gregoire, F. M., Zhang, Q., Smith, S. J., Tong, C. H., Ross, D. A., Lopez, H., & West, D. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00072.2001 · Cited by 115
Pοlyzos, S. A., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.013 · Cited by 115
Takeuchi, S., Matsuda, T., Kobayashi, S., Takahashi, T., & Kojima, H. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.08.011 · Cited by 106
Starner, C. I., Schafer, J. A., Heaton, A. H., et al. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.6.523 · Cited by 102
Gupte, A. A., Liu, J. Z., Ren, Y., Minze, L. J., Wiles, J. R., Collins, A. R., Lyon, C. J., Praticò, D., Finegold, M. J., Wong, S. T. C., et al. (2010) · Hepatology · doi:10.1002/hep.23941 · Cited by 101
Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice
Peters, J. M., Aoyama, T., Burns, A., & Gonzalez, F. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00065-9 · Cited by 100
Leclercq, I. A., Lebrun, V. A., Stärkel, P., & Horsmans, Y. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700489 · Cited by 100
Shan, W., Nicol, C. J. B., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2007) · Hepatology · doi:10.1002/hep.21925 · Cited by 99
Shan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97 · cited 2×
“While treatment with GW0742 resulted in improvement in fibrosis in wild type mice, this effect was not seen in PPARδ null mice demonstrating a PPARδ-dependent mechanism of action to alleviate fibrosis in response to this stimulus [60,61].”
BackgroundHarrity, T. W., Farrelly, D., Tieman, A., Chu, C., Kunselman, L., Gu, L., Ponticiello, R. P., Cap, M., Qu, F., Shao, C., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0648 · Cited by 89
Establishing the Role of PPARβ/δ in Carcinogenesis
Peters, J. M., Gonzalez, F. J., & Müller, R. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.004 · Cited by 86
Yu, J. Q., Zhang, S., Chu, E. S., Go, M. Y. Y., Lau, R. H. Y., Zhao, J., Wu, C., Tong, L., Zhao, J., Poon, T. C. W., et al. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.006 · Cited by 84
Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice
Nan, Y., Fu, N., Wu, W., Liang, B.-L., Wang, R., Zhao, S., Zhao, J., & Yu, J. Q. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520802530861 · Cited by 79
Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans
Hertz, R., & Bar‐Tana, J. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00290-2 · Cited by 71
Hall, A. M., Soufi, N., Chambers, K. T., Chen, Z., Schweitzer, G. G., McCommis, K. S., Erion, D. M., Graham, M. J., Su, X., & Finck, B. N. (2014) · Diabetes · doi:10.2337/db13-1502 · Cited by 71
Self-citationEl-Haleim, E. A. A., Bahgat, A. K., & Saleh, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i10.2931 · Cited by 69
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67
Lee, E. Y., Choi, R., Kim, H. M., Cho, E. J., Kim, B. H., Choi, Y. S., Naowaboot, J., Lee, E. Y., Yang, Y. C., Shin, J. Y., et al. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.10.066 · Cited by 66
Nan, Y., Han, F., Kong, L.-B., Zhao, S., Wang, R., Wu, W., & Yu, J. Q. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.525717 · Cited by 66
Brand, C. L., Sturis, J., Gotfredsen, C. F., Fleckner, J., Fledelius, C., Hansen, B. F., Andersen, B., Ye, J., Sauerberg, P., & Wassermann, K. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2002 · Cited by 62
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis
Fisher, C. D., Jackson, J. P., Lickteig, A. J., Augustine, L. M., & Cherrington, N. J. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0312-z · Cited by 59
Uto, H., Nakanishi, C., Ido, A., Hasuike, S., Kusumoto, K., Hirohiko, A. B. E., Numata, M., NAGATA, K., Hayashi, K., & Tsubouchi, H. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.05.008 · Cited by 57
Laughter, A., Dunn, C. S., Swanson, C. L., et al. (2004) · Toxicology · doi:10.1016/j.tox.2004.06.014 · Cited by 51
Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet
Hsiao, P., Hsieh, T., Kuo, K., Hung, W., Tsai, K., Yang, C.-H., Yu, M., & Shin, S. (2008) · BMC Molecular Biology · doi:10.1186/1471-2199-9-82 · Cited by 50
Cariou, B., Hanf, Lambert-Porcheron, S., & Zair (2013) · Diabetes Care · Cited by 49
Harnessing the benefits of PPARβ/δ agonists
Mackenzie, L. S., & Lione, L. A. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.10.022 · Cited by 45
Nakano, S., Nagasawa, T., Ijiro, T., Inada, Y., Tamura, T., Maruyama, K., Kuroda, J., Yamazaki, Y., Kusama, H., & Shibata, N. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00363.x · Cited by 42
Beysen, C., Murphy, E. J., Nagaraja, H. N., Decaris, M. L., Riiff, T. J., Fong, A., Hellerstein, M. K., & Boyle, P. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800165-jlr200 · Cited by 41
Corton, J. C. (2008) · Critical Reviews in Toxicology · doi:10.1080/10408440802209796 · Cited by 37
Redonnet, A., Groubet, R., Nöel-Suberville, C., Bonilla, S., Martı́nez, A., & Higueret, P. (2001) · Metabolism · doi:10.1053/meta.2001.26759 · Cited by 34
Zhang, N., Lu, Y., Shen, X., Bao, Y., Cheng, J., Chen, L., Bao, L., & Zhang, Q. (2015) · Pharmacology · doi:10.1159/000380952 · Cited by 31
PPARαIs Required for PPARδAction in Regulation of Body Weight and Hepatic Steatosis in Mice
Garbacz, W. G., Huang, J. T.-J., Higgins, L. G., Wahli, W., & Palmer, C. N. A. (2015) · PPAR Research · doi:10.1155/2015/927057 · Cited by 27
Balkrishnan, R., Arondekar, B. V., CAMACHO, F. T., Shenolikar, R. A., Horblyuk, R. V., & Anderson, R. T. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.019 · Cited by 20
Hamrén, B., Öhman, K. P., Svensson, M. K. E., & Karlsson, M. O. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011416937 · Cited by 20
Rosiglitazone Cools Down Inflammation in the Metabolic Syndrome
Esposito, K., Ciotola, M., Merante, D., & Giugliano, D. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000223874.94624.11 · Cited by 15
Modeling fatty liver disease in animals: Is there an optimal approach, and is the effort worthwhile?
Maher, J. J. (2016) · Hepatology · doi:10.1002/hep.28823 · Cited by 11
Rosiglitazone or pioglitazone in type 2 diabetes?
de Vries, C. S., & Russell-Jones, D. L. (2009) · BMJ · doi:10.1136/bmj.b3076 · Cited by 9
GW501516 acts as an efficient PPARα activator in the mouse liver
Terada, M., Araki, M., Ashibe, B., & Motojima, K. (2011) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2011.v5.4.176 · Cited by 6
Cited by
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
Metadata
- Authors
- Liss, K. H. H., & Finck, B. N.
- Venue
- Biochimie
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 136
- Pages
- 65-74
- ISSN
- 0037-9042 (ISSN-L)
- 0300-9084
- OpenAlex
- W2558996269
- Cited by
- 275
- References
- 131
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.